Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
June 17, 2025
Health Care Law Today
Oregon’s New Corporate Practice of Medicine Restrictions: Five Takeaways for Digital Health and Telemedicine Companies
On June 9, 2025, Oregon’s governor signed SB 951 into law, making Oregon one of the most restrictive states in the country with respect…
June 17, 2025
Foley Viewpoints
Federal Court Enforces Forum Selection Clause in Dealer Dispute with Equipment Manufacturer
A federal district court recently enforced a forum selection clause in National Equipment Dealers, LLC v. IROCK Crushers LLC,…
June 17, 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Mitigating Risks Posed by the New Trump Administration Focus on Drug Cartels and TCOs
The Trump Administration’s crackdown on cartels and transnational criminal organizations operating abroad and in the United States is a significant Department of Justice priority.